**ADVISORY COMMITTEE**

**of the** **Connecticut Bioscience Innovation Fund**

Minutes – Regular Meeting   
Wednesday, January 18, 2023

A regular meeting of the **Connecticut Bioscience Innovation Fund** (“the Bioscience Fund” or “CBIF”) **Advisory Committee** (the “Committee”) was held electronically through Microsoft Teams on January 18, 2023.

**1. Call to Order**:

Noting the presence of a quorum, Matt McCooe, Chairperson of the Committee, called the meeting to order at 10:01 a.m.

Committee Members Present: Peter Farina, Ph.D.; Seth Feuerstein; Charles Lee, Ph.D.; Matt McCooe; Chris McLeod; Alan Mendelson; Anthony Muyombwe, Ph.D.; Kevin Rakin; David Scheer; Jonathan Soderstrom, Ph.D.; and Sandra Weller, Ph. D.

Committee Members Absent: Alexandra Daum; and William LaRochelle, Ph.D.

Staff Attending: Cyndi Green, Ph. D.; Stepheni Harpin; Malik Lewis, Ph.D.; Peter Longo; Matthew McCooe; Pauline Murphy; Elizabeth Skrabl; Matthew Storeygard; Daniel Wagner; and Renee Wasko.

**2. Approval of Minutes:**

Mr. McCooe asked the Committee members to consider the minutes from the December 5, 2022, special meeting.

**Upon a motion made by Mr. McLeod and seconded by Dr. Farina, the Advisory Committee members voted** **unanimously in favor of adopting the minutes from the December 5, 2022, special meeting, as presented.**

**3. Other Business:**

**“Invea Therapeutics, Inc. – Guilford, CT”**

Mr. Wagner discussed the Invea Therapeutics, Inc. investment proposal and outlined the proposed revisions to the resolution date from that presented in the December 5, 2022, Connecticut Bioscience Innovation Fund Advisory Committee special meeting.

A discussion ensued.

**Upon a motion made by Mr. McLeod and seconded by Dr. Soderstrom, the Advisory Committee members voted unanimously in favor of approving the extension of the resolution date to June 30, 2023, as presented, in Invea Therapeutics, Inc.**

**“Summit Steet Medical, Inc – Wallingford, CT”**

Ms. Murphy discussed the history of CI’s investment in Summit Street Medical, Inc. and the current strategic plan of the company.

A discussion ensued.

**Upon a motion made by Mr. Scheer and seconded by Mr. Rakin, the Advisory Committee members voted, with one abstention, in favor of the execution by Connecticut Innovations, Inc. (“CI”) on items for action, as presented, in Summit Street Medical, Inc.**

**“Pre-Seed and Internal Approvals - CI Ventures Update for the quarter ended December 31, 2022.”**

Ms. Murphy gave a brief presentation on the Pre-Seed and Internal Approvals - CI Ventures Update for the quarter ended December 31, 2022.

**Upon a motion made by Dr. Lee and seconded by Dr. Soderstrom, the Advisory Committee members voted unanimously in favor of approving the Memorandum entitled "Pre-Seed and Internal Approvals – CI Ventures Update for the quarter ended December 31, 2022” as presented.**

**“****DiA Imaging Analysis, Inc. – Tel Aviv, Israel”**

Mr. Longo discussed the history of CI’s investment in DiA Imaging Analysis, Inc., and the current strategic plan of the company.

A discussion ensued.

**Upon a motion made by Mr. McLeod and seconded by Mr. Scheer, the Advisory Committee members voted unanimously in favor of the execution by Connecticut Innovations, Inc. (“CI”) on items for action, as presented, in DiA Imaging Analysis, Inc.**

**4. Date of Next Meeting:**

February 15, 2023, at 10:00 a.m.

**5. Adjournment:**

**Upon a motion made by Dr. Lee, seconded by Dr. Feuerstein, the Advisory Committee members voted unanimously in favor of adjourning the meeting at 10:34 a.m.**

Respectfully Submitted,

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Matthew McCooe

Chairperson